Emerging targeted therapies for melanoma

Area of Science:

• Oncology
• Dermatology
• Cancer Therapeutics

Background:

• Melanoma is an aggressive skin cancer with limited response to traditional treatments.
• Recent advances include immune checkpoint inhibitors and BRAF-targeted agents for advanced melanoma.
• Therapeutic resistance remains a significant challenge, driving the need for novel treatment strategies.

Purpose of the Study:

• To review current melanoma treatments, including immune and molecularly-targeted therapies.
• To discuss emerging targeted agents and novel therapeutic approaches in development.
• To highlight the ongoing need for more effective melanoma therapies.

Main Methods:

• Comprehensive review of existing and investigational melanoma treatments.
• Focus on molecularly-targeted therapies, including mitogen-activated protein kinase (MAPK) pathway inhibitors.
• Exploration of novel approaches like antibody-drug conjugates and cell-cycle targeting.

Main Results:

• Significant progress has been made in melanoma therapeutics.
• Primary or acquired resistance to current treatments affects most patients.
• Numerous molecular targets offer potential for new therapy development.

Conclusions:

• Despite advances, more effective melanoma therapies are urgently needed.
• Molecularly-targeted therapies are expected to be a cornerstone of future melanoma treatment.
• Combined strategies involving targeted and immune therapies will likely improve patient outcomes.